Pioneering a Differentiated Approach to Targeted Protein Degradation Using the Ubiquitin Conjugating Enzyme (E2) Family
Time: 2:15 pm
day: Day 1, Track 2, PM
Details:
- Overcoming the challenge of modulating ubiquitin-conjugating enzymes with small molecules by identifying novel strategies to address the lack of druggable pockets
- Leveraging Fragment-Based Drug Design for PTM-E2 complexes to enable the discovery of first-in-class ligands that open new therapeutic avenues
- Developing efficacious bi-functional degraders through E2 ligand extension and molecular design to target multiple high-value proteins of interest
